Nicholas Plotnikoff - Immune Therapeutics Non-Executive Chairman of the Board
| IMUNDelisted Stock | USD 0.06 0 4.76% |
Chairman
Dr. Nicholas Plotnikoff is NonExecutive Chairman of the Board of the Company. Dr. Plotnikoff has a Ph.D. in Pharmacology and over 20 years experience in the pharmaceutical industry working in Pharmacology, Toxicology, and Clinical Research. Prior to joining our Board, Dr. Plotnikoff was a Professor of Pharmacology at the University of Illinois Medical Center in Chicago from December 1987 until his retirement in May 2008. Dr. Plotnikoff formed TNI Pharmaceutical, Inc. in 1987, which became a public company in 1991. Dr. Plotnikoff served as its Chief Executive Officer and President for 20 years where he helped develop the immunological effects of MENK. He successfully managed the project teams that developed the new drug applications for Traxene and Cylert . Dr. Plotnikoff was responsible for the Phase I and Phase II trials for MENK in HIVAIDS. In basic research, he was the first to identify the central nervous system effects of hypothalamic releasing factors, resulting in clinical development for treatment of depression and Parkinsons disease. Dr. Plotnikoff has coauthored 25 publications with Dr. Andrew Schally, covering basic research in the field of depression and Parkinsons disease. Dr. Plotnikoff was issued a number of international patents for the use of MENK in HIVAIDS and cancer, which we acquired in 2012. since 2012.
| Age | 87 |
| Tenure | 12 years |
| Phone | 888 613 8802 |
| Web | https://www.immunetherapeutics.com |
Immune Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.4526) % which means that it has lost $0.4526 on every $100 spent on assets. This is way below average. Immune Therapeutics' management efficiency ratios could be used to measure how well Immune Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 1.08 M in liabilities with Debt to Equity (D/E) ratio of 1.97, which is about average as compared to similar companies. Immune Therapeutics has a current ratio of 0.04, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Immune Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Immune Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Immune Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Immune to invest in growth at high rates of return. When we think about Immune Therapeutics' use of debt, we should always consider it together with cash and equity.
Immune Therapeutics, Inc. does not have significant operations. Immune Therapeutics, Inc. is headquartered in Orlando, Florida. Immune Therapeutics operates under Biotechnology classification in the United States and is traded on OTC Exchange. Immune Therapeutics [IMUN] is a Pink Sheet which is traded through a dealer network over-the-counter (OTC). Management Performance
| Return On Asset | -0.45 |
Immune Therapeutics Leadership Team
Elected by the shareholders, the Immune Therapeutics' board of directors comprises two types of representatives: Immune Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Immune. The board's role is to monitor Immune Therapeutics' management team and ensure that shareholders' interests are well served. Immune Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Immune Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kevin Phelps, Director | ||
| Peter Aronstam, CFO | ||
| Christopher Pearce, COO, Director | ||
| FMedSci FRACP, Chief RD | ||
| Jack Brewer, Director | ||
| Glen MBA, Chief Officer | ||
| Clifford Selsky, Independent Director | ||
| Nicholas Plotnikoff, Non-Executive Chairman of the Board | ||
| Fengping Shan, Chief Science Officer | ||
| Noreen Griffin, Founder, Chairman and CEO | ||
| Edward Teraskiewicz, Independent Director | ||
| Joseph Fortunak, VP of Global RandD and Chemical Devel. and Member of Advisory Board | ||
| Paul Akin, Independent Director | ||
| Rudy Williams, COO | ||
| Kelly Wilson, Interim Pres |
Immune Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Immune Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -0.45 | |||
| Current Valuation | 83.25 M | |||
| Shares Outstanding | 82.76 M | |||
| Shares Owned By Insiders | 29.51 % | |||
| Price To Earning | 333.33 X | |||
| Price To Sales | 161.50 X | |||
| Gross Profit | 65.83 K | |||
| EBITDA | 3.8 M | |||
| Net Income | 3.59 M | |||
| Cash And Equivalents | 271.53 K |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Immune Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Immune Therapeutics' short interest history, or implied volatility extrapolated from Immune Therapeutics options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Other Consideration for investing in Immune Pink Sheet
If you are still planning to invest in Immune Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Immune Therapeutics' history and understand the potential risks before investing.
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |